Cell News and Research

RSS

Palmetto establishes formal coverage policy for all Medicare patients

Genomic Health, Inc. today announced that Palmetto GBA, the designated national contractor for its Oncotype DX colon cancer test, has established a formal coverage policy for all Medicare patients.

1 Oct 2011

Less toxic amounts of chemotherapy medicine slows tumor growth: Scientists

University of Georgia scientists have found that smaller, less toxic amounts of chemotherapy medicine given frequently to mice with human prostate cancer noticeably slowed tumor growth.

1 Oct 2011

Researchers identify gene responsible for starting the biological clock

Ever wondered why you wake up in the morning ---- even when the alarm clock isn't making jarring noises? Wonder no more. Researchers at the Salk Institute for Biological Studies have identified a new component of the biological clock, a gene responsible for starting the clock from its restful state every morning.

1 Oct 2011

NIH's fourth Symposium on Cardiovascular Regenerative Medicine to be held Oct. 4-5

Advances in tissue engineering and stem cell therapies will be among the research topics discussed during the National Institutes of Health's fourth Symposium on Cardiovascular Regenerative Medicine, which will be held Oct. 4-5.

1 Oct 2011

Pfizer releases Phase III study results comparing VFEND-ERAXIS combination to VFEND for IA

Pfizer Inc. today reported the top-line results of an international Phase III clinical trial which compared the combination of VFEND (voriconazole) and ERAXISTM (anidulafungin) to VFEND monotherapy for primary therapy of invasive aspergillosis, a life-threatening invasive fungal infection that can develop as a complication in patients with compromised immune systems.

1 Oct 2011

Novel bipartite gene therapy for retinitis pigmentosa

In a paper published in the October 2011 issue of Experimental Biology and Medicine, a team of researchers at Columbia University Medical Center led by Stephen Tsang, MD, Ph.D have achieved temporary functional preservation of photoreceptors in a mouse model for retinitis pigmentosa (RP) using novel bipartite gene therapy.

1 Oct 2011

ViroPharma licenses worldwide rights from Intellect Neurosciences to OX1 for treatment of FA

ViroPharma Incorporated today announced the license of worldwide rights from Intellect Neurosciences, Inc. to its clinical stage drug candidate, OX1, being developed for the treatment of Friedreich's Ataxia (FA), a rare, hereditary, progressive neurodegenerative disease.

1 Oct 2011

European and North American scientists to explore biology of heart failure

A collaborative network of European and North American scientists, including from the University of North Carolina at Chapel Hill School of Medicine, have been awarded a total of $6 million over five years to explore the biology of heart failure and to find new therapies for it.

1 Oct 2011

Scientists discover that DNA modifications in brain cells change due to stimulated brain activity

Johns Hopkins scientists investigating chemical modifications across the genomes of adult mice have discovered that DNA modifications in non-dividing brain cells, thought to be inherently stable, instead underwent large-scale dynamic changes as a result of stimulated brain activity.

1 Oct 2011

UCI study shows promise of metabolic therapy for autoimmune diseases

A glucosamine-like dietary supplement suppresses the damaging autoimmune response seen in multiple sclerosis, according to a UC Irvine study.

1 Oct 2011

Novel binding assay can simplify search for potential SERT inhibitors

Many psychiatric conditions are caused by aberrant metabolism of the neurotransmitter serotonin. Researchers in the Department of Pharmacy at LMU have now developed a new screening method, which will facilitate the search for new drugs that modulate the biological activity of serotonin.

1 Oct 2011

Circadian subsidiary submits IND application to FDA to initiate VGX-100 study against cancer

Circadian Technologies Limited is extremely proud to announce that its 100% owned subsidiary, Vegenics Pty Ltd, has submitted an investigational new drug application to the U.S. Food and Drug Administration to initiate clinical studies of VGX-100.

1 Oct 2011

ADVENTRX holds Type A meeting with FDA to discuss Exelbine NDA

ADVENTRX Pharmaceuticals, Inc. announced today that it held a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the complete response letter (CRL) it received in August from the FDA regarding the Company's New Drug Application (NDA) for Exelbine (vinorelbine injectable emulsion) for the treatment of non-small cell lung cancer.

1 Oct 2011

UC San Diego professor receives NIDDK grant to study kidney complications related to diabetes

Kumar Sharma, MD, FAHA, professor of medicine at the University of California, San Diego School of Medicine and director of the Center for Renal Translational Medicine, has received a $5.9 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health, to study kidney complications related to type 1 and type 2 diabetes.

1 Oct 2011

Researchers discover new inherited disorder that causes mental retardation, liver dysfunction

Researchers at the Swedish medical university Karolinska Institutet have discovered a new inherited disorder that causes severe mental retardation and liver dysfunction. The disease, adenosine kinase deficiency, is caused by mutations in the ADK gene, which codes for the enzyme adenosine kinase.

1 Oct 2011

Study demonstrates how the intestine maintains 'immune tolerance' under healthy conditions

Imagine a single drug that would treat most, if not all, autoimmune disorders, such as asthma, inflammatory bowel disease, and Lupus. That might not be so hard to do thanks to a team of researchers who have discovered a molecule normally used by the body to prevent unnecessary immune reactions.

30 Sep 2011

The 7th annual World Stem Cell Summit takes place in Pasadena, CA

Stem cell research and regenerative medicine has long held the potential to treat serious medical conditions, but only recently has the industry as a whole begun to take shape. What was once confined within the realm of research and academia is now attracting the interest of corporations and philanthropists who are investing large amounts of money into this promising science.

30 Sep 2011

New targeting approach to develop an active site-directed, drug-like PTP1B inhibitor

The work of a team of scientists at Cold Spring Harbor Laboratory (CSHL) led by Professor Nicholas Tonks FRS, suggests a way to overcome one of the major technical obstacles preventing a leading therapeutic target for diabetes and obesity from being addressed successfully by novel drugs.

30 Sep 2011

Fat-rich 'western diet' fuels cardiovascular disease, type 2 diabetes and obesity

A major risk factor for cardiovascular disease, type 2 diabetes and other health- and life-threatening conditions, obesity is epidemic in the United States and other developed nations where it's fueled in large part by excessive consumption of a fat-rich "Western diet."

30 Sep 2011

Free radical peroyxnitrite linked to failure of cytotoxic T-cells to eliminate tumors

Researchers at the Moffitt Cancer Center in Tampa, Fla., and colleagues have found that tumor cell resistance to a specific cancer immunotherapy designed to kill cancer cells can be blamed on a mechanism that involves the production of a free radical peroxynitrite (PNT) that causes resistance to therapeutic cancer-killing cells.

30 Sep 2011

Cell News and Research

Palmetto establishes formal coverage policy for all Medicare patients

Less toxic amounts of chemotherapy medicine slows tumor growth: Scientists

Researchers identify gene responsible for starting the biological clock

NIH's fourth Symposium on Cardiovascular Regenerative Medicine to be held Oct. 4-5

Pfizer releases Phase III study results comparing VFEND-ERAXIS combination to VFEND for IA

Novel bipartite gene therapy for retinitis pigmentosa

ViroPharma licenses worldwide rights from Intellect Neurosciences to OX1 for treatment of FA

European and North American scientists to explore biology of heart failure

Scientists discover that DNA modifications in brain cells change due to stimulated brain activity

UCI study shows promise of metabolic therapy for autoimmune diseases

Novel binding assay can simplify search for potential SERT inhibitors

Circadian subsidiary submits IND application to FDA to initiate VGX-100 study against cancer

ADVENTRX holds Type A meeting with FDA to discuss Exelbine NDA

UC San Diego professor receives NIDDK grant to study kidney complications related to diabetes

Researchers discover new inherited disorder that causes mental retardation, liver dysfunction

Study demonstrates how the intestine maintains 'immune tolerance' under healthy conditions

The 7th annual World Stem Cell Summit takes place in Pasadena, CA

New targeting approach to develop an active site-directed, drug-like PTP1B inhibitor

Fat-rich 'western diet' fuels cardiovascular disease, type 2 diabetes and obesity

Free radical peroyxnitrite linked to failure of cytotoxic T-cells to eliminate tumors

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News